• Ceretype Neuromedicine

  Participated · Seed · Jan 2024

  Ceretype Neuromedicine is a Cambridge, MA-based company that focuses on the practical application and integration of functional MRI (fMRI) in neuropsychiatric drug development and beyond. Led by CEO Emily Stern, the company’s platform makes targeted biomarkers accessible and delivers actionable evidence to improve drug discovery and patient care. Through its technical approach and its ability to sub-type and classify the human brain on a neurobiological level, Ceretype offers biologically-based therapeutic insights. The company closed its second round of seed financing with a $2M funding target that was oversubscribed. Ceretype intends to use the funds to help advance its fMRI platform. Investors in the round included Cedar Street Group as lead, along with Leafy Tunnel, The One Mind Accelerator and private investors.

• Tetra Pharm

  Participated · Series A · Jan 2023

  Tetra Pharm Technologies is a Copenhagen-based biopharmaceutical company developing therapeutics that target the endocannabinoid system to treat neuropathic pain and mental health disorders. The company is led by CEO Martin Rose. It recently completed a €9M Series A and intends to use the proceeds to increase research and development capacity and expand commercial operations internationally. In 2022 the company closed several significant distribution deals across its main European markets. Tetra Pharm expects to release its first product to treat neuropathic pain in February 2023.

• Lyphe group

  Led · Series A · May 2022

  Lyphe is a London-based medical cannabis ecosystem offering patient care, medical treatments and direct-to-patient digital services. It operates a digital-first patient-access platform that provides clinics, dispensing, import infrastructure and educational services to patients, doctors and the industry. The company supports telehealth, dispensing and technology services via a team of more than 100 employees. Lyphe intends to use the new funding to expand into multiple markets across Europe. The £5m Series A follows a strong 2021 for Lyphe Group, when revenues increased by more than 250% year-over-year. CEO Jonathan Nadler framed the business as a digital-first patient-access ecosystem serving patients, clinicians and the wider industry.

• Maya Health

  Led · Seed · Dec 2021

  Maya Health (Maya PBC) operates a real-world data platform and product suite that includes a Companion App for individuals, a Measurement Based Care Platform for providers, and a Real World Data Platform for researchers. The company positions itself to bridge psychedelic research and real-world practice by enabling collaboration among providers, participants, researchers, and regulators. It plans to bring its platform to market in 2022 and to expand personnel, develop its technologies, add business integrations for practitioners, and integrate with blockchain initiatives to enhance security, privacy, and transparency. Financially, Maya announced $4.3 million in its first investment rounds, consisting of an $800,000 angel round and a $3.5 million seed round. The platform is intended to accelerate pre-clinical research, enhance safety, optimize outcomes, and help reduce the cost of psychedelic care. Maya frames its mission around scaling psychedelic healthcare safely and effectively as a public benefit corporation based in Denver.

• Beckley Psytech

  Participated · Series B · Aug 2021

  Beckley Psytech is a British privately-held psychedelic drug developer focused on short-duration psychedelic therapies. Its two primary clinical programs are intranasal 5‑MeO‑DMT (BPL‑003), in a Phase IIb study targeting 225 moderate-to-severe TRD patients with a readout expected in H2 2024, and intravenous psilocin (ELE‑101), in a Phase I/IIa study with topline results expected in H1 2024. The company positions these shorter-duration candidates as potentially more scalable and efficient than longer-acting psychedelic-assisted therapies, which could improve patient access. Beckley and its partners are exploring digital patient-support tools and planning for future commercialization as part of development efforts. Financially, Beckley received a $50M strategic investment from atai—$40M primary and $10M secondary—which granted atai a 35.47% stake and board representation. The company previously raised an $80M Series B (upsized from $50M) in summer 2021. Beckley Psytech is a clinical-stage, privately held company developing a broad pipeline of psychedelic compounds to address neurological and psychiatric disorders. Its near-term clinical programs include a Phase 1b low-dose psilocybin trial in patients with SUNHA and a planned Phase 1 dose-ranging study of an intranasal 5-MeO-DMT formulation ahead of a Phase 2 trial in treatment-resistant depression. The company plans to expand its pipeline with new, unique and proprietary psychedelic compounds. Beckley Psytech leverages expertise developed over more than 20 years by the Beckley Foundation and was founded in 2019. It is based in Oxford, United Kingdom and states a vision for integrating clinically validated psychedelic medicines into modern medical practice. The company recently completed an oversubscribed Series B financing of $80 million to accelerate its clinical development programs. Beckley Psytech is a UK psychedelic medicine company and spin-out of the Beckley Foundation focused on turning psychedelic compounds into licensed pharmaceuticals. Its immediate focus is the development of 5-MeO-DMT as a treatment for neuropsychiatric diseases and the company is preparing to begin a Phase 1 clinical trial. The team also plans to explore other psychedelic agents targeting orphan diseases. The company was founded last year by Lady Amanda Feilding and CEO Cosmo Feilding Mellen and maintains a Scientific Advisory Board including Dr. Robin Carhart-Harris, Prof. Matthew Johnson and Prof. Guy Goodwin. Financially, the company has recently completed follow-on fundraising to push its drug development pipeline toward clinical trials.

No current team members are available.